Home › Multiple Sclerosis › New Jersey › Edison
Multiple Sclerosis clinical trials in Edison, NJ
3 studies for Multiple Sclerosis are looking for participants at sites in and around Edison (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- Rutgers Cancer Institute of New Jersey, New Brunswick · 3 mi away
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
RecruitingObservational study
- TG Therapeutics Investigational Trial Site, Bridgewater · 14 mi away
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RecruitingPhase 3
- Local Institution - 0131, New Brunswick · 3 mi away
About Multiple Sclerosis
Multiple sclerosis (MS) slows down or blocks messages between the brain and body. MS can be mild or severe. Learn about MS symptoms and treatment.
More about Multiple Sclerosis on MedlinePlus
Multiple Sclerosis trials in other cities
- New York City, NY17 studies
- Chicago, IL15 studies
- Boston, MA14 studies
- Washington, DC13 studies
- Cleveland, OH10 studies
- Birmingham, AL9 studies
- Aurora, CO8 studies
- Kansas City, KS8 studies
- St. Louis, MO8 studies
- San Francisco, CA8 studies
- Tampa, FL7 studies
- Dallas, TX7 studies
Other studies in Edison
- Breast Cancer70 studies
- Non-Small Cell Lung Cancer50 studies
- Cancer (all types)33 studies
- Prostate Cancer29 studies
- Colorectal Cancer25 studies
- Lung Cancer25 studies
- Bladder Cancer23 studies
- Multiple Myeloma21 studies
- Metastatic Cancer20 studies
- Endometrial Cancer20 studies
- Acute Myeloid Leukemia20 studies
- Ovarian Cancer19 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.